Click Therapeutics' digital therapeutic (DTx) CT-132 has been approved by the FDA, becoming the first treatment of its type in the US for preventing attacks in people with episodic migraine.

Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder. Rejoyn (formerly CT-152), a ...

Emerging technologies not only expedite the development of new drugs, but also introduce a completely new class of therapies, such as digital therapeutics (DTx), which are software-based solutions ...